Alexion Pharmaceuticals Inc (ALXN)

ALXN (NASDAQ:Drugs) EQUITY
$180.77
pos +3.01
+1.69%
Today's Range: 175.83 - 181.52 | ALXN Avg Daily Volume: 2,120,900
Last Update: 06/30/15 - 4:00 PM EDT
Volume: 2,953,827
YTD Performance: -0.31%
Open: $180.50
Previous Close: $177.76
52 Week Range: $150.06 - $203.30
Oustanding Shares: 199,576,769
Market Cap: 36,811,935,042
6-Month Chart
TheStreet Ratings Grade for ALXN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 14 14 14 13
Moderate Buy 1 1 1 1
Hold 2 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.26 1.16 1.16 1.17
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 63.17
Price Earnings Comparisons:
ALXN Sector Avg. S&P 500
63.17 63.20 26.65
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
4.78% 11.00% 89.41%
GROWTH 12 Mo 3 Yr CAGR
Revenue 44.00 1.85 0.41
Net Income 159.80 2.75 0.55
EPS 157.30 2.46 0.51
Earnings for ALXN:
EBITDA 0.98B
Revenue 2.23B
Average Earnings Estimates
Qtr (06/15) Qtr (09/15) FY (12/15) FY (12/16)
Average Estimate $1.30 $1.38 $5.29 $7.25
Number of Analysts 2 2 2 2
High Estimate $1.31 $1.43 $5.44 $7.28
Low Estimate $1.30 $1.34 $5.14 $7.22
Prior Year $0.99 $1.14 $4.64 $5.29
Growth Rate (Year over Year) 31.82% 21.49% 14.01% 37.05%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Jim Cramer

 | May 18, 2015 | 3:24 PM EDT

Acquisitions cut into overabundance of companies.

By

David Peltier

 | May 6, 2015 | 4:52 PM EDT

U.S. stocks fell for a second straight session.

By

Jim Cramer

 | Mar 23, 2015 | 6:00 AM EDT

Here are healthcare stocks of all shares and sizes with strong charts.

bearishAlexion estimates, target cut at Credit Suisse

Jan 30, 2015 | 7:49 AM EST

Shares of ALXN now seen reaching $186, according to Credit Suisse. Estimates also reduced, given the company's currency headwinds. Neutral rating. 

By

Timothy Collins

 | Jan 8, 2015 | 10:09 AM EST
Do you need to pick one name?
By

Kate Stalter

 | Jan 6, 2015 | 12:00 PM EST

They are prone to being whipsawed by news.

bearishAlexion downgraded at Morgan Stanley

Jan 5, 2015 | 6:36 AM EST

ALXN was downgraded from Overweight to Equal-weight, Morgan Stanley said. $202 price target. Valuation call, as the company has limited near-term catalysts. 

By

Bob Byrne

 | Nov 13, 2014 | 7:30 AM EST

A few stocks that could break higher.

By

Carolyn Boroden

 | Nov 3, 2014 | 8:30 AM EST

As these examples illustrate, it's just good risk management.

By

Kate Stalter

 | Oct 30, 2014 | 2:00 PM EDT

Some growth leaders in the sector are getting technical support.

Is it just me or has there been a distinct lack of negative pre-earnings announcements thu...
With one of the biggest moves ever in ONE DAY yesterday (top 10 all time), the market is s...

Risky CMBS tranches price at widest levels since 2013.

Sure the bulls are more fearful, if only for one reason. After a 6-plus year bull market, ...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.